Therapeutic | Rivabazumab |
Target | PcrV type III secretion system |
Heavy Chain | EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS |
Light Chain | DIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Fab |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | Humaneering Technology |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | KaloBios Pharmaceuticals Inc |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Infectiology, Inflammation, Inherited diseases |
Notes |